复旦大学附属华山医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma12 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma62 篇牵头论文牵头 1 项开放试验
- 胃癌Stomach cancer22 篇牵头论文牵头 6 项开放试验
- 脊索瘤Chordoma4 篇牵头论文
- 骨肉瘤Osteosarcoma2 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
- 神经母细胞瘤Neuroblastoma1 篇牵头论文
- 尤文肉瘤Ewing sarcoma0 篇牵头论文
- 多发性骨髓瘤Multiple myeloma5 篇牵头论文
- 血友病 AHaemophilia A1 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder23 篇牵头论文牵头 1 项开放试验
- IgG4相关性疾病IgG4-related disease0 篇牵头论文
- 重症肌无力Myasthenia gravis31 篇牵头论文牵头 4 项开放试验
- 烟雾病Moyamoya disease17 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis7 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis10 篇牵头论文
- 脊髓性肌萎缩症Spinal muscular atrophy11 篇牵头论文
- 庞贝病Pompe disease1 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
- 白塞病Behçet disease1 篇牵头论文
- IgA 肾病IgA nephropathy6 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
- 遗传性大疱性表皮松解症Inherited epidermolysis bullosa2 篇牵头论文
- 遗传性血管性水肿Hereditary angioedema1 篇牵头论文
未列出的收录疾病:鼻咽癌、肝母细胞瘤、视网膜母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、法布雷病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、先天性巨结肠、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文12
- The carcinogenesis of esophageal squamous cell cancer is positively regulated by USP13 through WISP1 deubiquitination.
- The comprehensive oral microbiome landscape unveils its interplay with poor oral health in esophageal squamous cell carcinoma risk.
- Cancer-associated fibroblasts promote growth and dissemination of esophageal squamous cell carcinoma cells by secreting WNT family member 5A.
- Metabolism score and machine learning models for the prediction of esophageal squamous cell carcinoma progression.
- Rad51 and Systemic Inflammatory Indicators as Novel Prognostic Markers in Esophageal Squamous Cell Carcinoma.
- Reconstruction using the colon or jejunum in patients with synchronous advanced esophageal and gastric cancers: a retrospective study from a single institutional database.
- Dasabuvir suppresses esophageal squamous cell carcinoma growth in vitro and in vivo through targeting ROCK1.
- Single-cell sequencing of multi-region resolves geospatial architecture and therapeutic target of endothelial cells in esophageal squamous cell carcinoma.
- Grading criteria for venous invasion in thoracic esophageal squamous cell carcinoma.
- ESRRG-PKM2 axis reprograms metabolism to suppress esophageal squamous carcinoma progression and enhance anti-PD-1 therapy efficacy.
- The prognostic value of separate lymphatic invasion and vascular invasion in oesophageal squamous cell carcinoma: a meta-analysis and systematic review.
- Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.
PubMed 以外找到的论文(未计入)9
- 148P Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
- Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 62 篇,占 0.4%。
上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
- 分期
- 不分期
- 开始
- 2025-12
- 登记号
- NCT07268131
年龄 18 岁 至 75 岁(登记的条件)
牵头:复旦大学附属华山医院上海
- 正在招募Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
- 分期
- II期
- 开始
- 2025-11
- 登记号
- NCT07331883
年龄 18 岁 至 75 岁(登记的条件)
牵头:上海交通大学医学院附属瑞金医院;另有 2 家列出的医院为研究中心上海、长春
- 正在招募Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- 分期
- 未注明
- 开始
- 2022-09
- 登记号
- NCT06822413
年龄未注明(登记的条件)
牵头:浙江大学医学院附属第二医院;另有 3 家列出的医院为研究中心上海、南昌、杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文62
- A Predictive Model Study on Differentiating Intrahepatic Cholangiocarcinoma From Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound, Shear Wave Elastography, and Clinical Feature-Based Nomogram.
- Activatable Sulfur Dioxide Nanosonosensitizer Enables Precisely Controllable Sono-Gaseous Checkpoint Trimodal Therapy for Orthotopic Hepatocellular Carcinoma.
- Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patients.
- Nanomedicine-unlocked radiofrequency dynamic therapy dampens incomplete radiofrequency ablation-arised immunosuppression to suppress cancer relapse.
- Comparison of 11C-Acetate and 18F-FDG PET/CT for Immune Infiltration and Prognosis in Hepatocellular Carcinoma.
- Population stratification using MASLD polygenic risk score improves severe liver disease prediction by clinical fibrosis scores.
- Prognostic and diagnostic value of [18F]FDG, 11C-acetate, and [68Ga]Ga-FAPI-04 PET/CT for hepatocellular carcinoma.
- A novel nomogram to predict the recurrence of hepatocellular carcinoma after liver transplantation using extended selection criteria.
- Adjuvant lenvatinib in combination with transarterial chemoembolization for hepatocellular carcinoma patients with high risk of postoperative recurrence: A multicenter prospective cohort study.
- Integrated Genetic Information of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Traits Improves Hepatocellular Carcinoma Risk Stratification and Screening.
- HBV sequence integrated to enhancer acting as oncogenic driver epigenetically promotes hepatocellular carcinoma development.
- Cholesterol suppresses AMFR-mediated PDL1 ubiquitination and degradation in HCC.
- Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma.
- The Absence of Intra-Tumoral Tertiary Lymphoid Structures is Associated with a Worse Prognosis and mTOR Signaling Activation in Hepatocellular Carcinoma with Liver Transplantation: A Multicenter Retrospective Study.
- Deciphering the role of KLRB1: a novel prognostic indicator in hepatocellular carcinoma.
- Cross-institutional evaluation of deep learning and radiomics models in predicting microvascular invasion in hepatocellular carcinoma: validity, robustness, and ultrasound modality efficacy comparison.
- Acetyl-CoA metabolic accumulation promotes hepatocellular carcinoma metastasis via enhancing CXCL1-dependent infiltration of tumor-associated neutrophils.
- Circular RNA circESYT2 serves as a microRNA-665 sponge to promote the progression of hepatocellular carcinoma through ENO2.
- ASB3 promotes hepatocellular carcinoma progression by mediating DR5 ubiquitination in TRAIL resistance.
- Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma.
- Integration of single-cell and spatial transcriptome sequencing identifies CDKN2A as a senescent biomarker in endothelial cells implicating hepatocellular carcinoma malignancy.
- Immune- and metabolism-related gene signature analysis uncovers the prognostic and immune microenvironments of hepatocellular carcinoma.
- Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.
- Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.
- Preoperative Ultrasound Radomics to Predict Posthepatectomy Liver Failure in Patients With Hepatocellular Carcinoma.
- Stomatin-like protein 2 promotes cell proliferation and survival under 5-Fluorouracil stress in hepatocellular carcinoma.
- Automatic segmentation of hepatocellular carcinoma on dynamic contrast-enhanced MRI based on deep learning.
- Nuclear translocation of metabolic enzyme PKM2 participates in high glucose-promoted HCC metastasis by strengthening immunosuppressive environment.
- Nomogram based on liver stiffness and spleen area with ultrasound for posthepatectomy liver failure: A multicenter study.
- Spleen to non-cancerous liver volume ratio predicts liver cirrhosis in hepatocellular carcinoma patients.
- SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway.
- Fusing Positive and Negative CT Contrast Nanoagent for the Sensitive Detection of Hepatoma.
- Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.
- The m6A-related gene signature stratifies poor prognosis patients and characterizes immunosuppressive microenvironment in hepatocellular carcinoma.
- The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma.
- An Angiogenic Gene Signature for Prediction of the Prognosis and Therapeutic Responses of Hepatocellular Carcinoma.
- CircularRNA Hsa_circ_0093335 promotes hepatocellular carcinoma progression via sponging miR-338-5p.
- Alcohol consumption and hepatocellular carcinoma: novel insights from a prospective cohort study and nonlinear Mendelian randomization analysis.
- Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.
- 27-Hydroxycholesterol promotes metastasis by SULT2A1-dependent alteration in hepatocellular carcinoma.
- Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma.
- The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma.
- LncRNA GASAL1 promotes hepatocellular carcinoma progression by up-regulating USP10-stabilized PCNA.
- Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma.
- Significance of Identifying Key Genes Involved in HBV-Related Hepatocellular Carcinoma for Primary Care Surveillance of Patients with Cirrhosis.
- Immunotherapy for hepatobiliary malignancies: Progress and prospective.
- Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.
- Biomarkers for response to immunotherapy in hepatobiliary malignancies.
- Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
- Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study.
- RNF4 silencing induces cell growth arrest and DNA damage by promoting nuclear targeting of p62 in hepatocellular carcinoma.
- A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
- Predictive Value of Platelet-Related Measures in Patients with Hepatocellular Carcinoma.
- Radiomics for the detection of microvascular invasion in hepatocellular carcinoma.
- Integrated bioinformatics analysis revealed the regulation of angiogenesis by tumor cells in hepatocellular carcinoma.
- MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.
- Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
- S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma.
- STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.
- Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1): A Novel Predictor for Recurrence of Hepatocellular Carcinoma After Curative Resection.
- GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages.
- Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3.
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
- A Study of [68Ga]Ga-NOTA-RG2 PET Imaging in the Diagnosis of Hepatocellular Carcinoma
- Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma
- The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection
- TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
- PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC
- Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
- Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
- Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma
- Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
- Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
- A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 22 篇,占 0.2%。
上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 7
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
- 分期
- 早期I期
- 开始
- 2026-06
- 登记号
- NCT07707531
年龄 18 岁 至 未注明(登记的条件)
牵头:复旦大学附属华山医院上海
- 正在招募A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
- 分期
- 不分期
- 开始
- 2024-01
- 登记号
- NCT06300879
年龄 18 岁 至 75 岁(登记的条件)
牵头:复旦大学附属华山医院上海
- 正在招募Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
- 分期
- 不分期
- 开始
- 2024-12
- 登记号
- NCT06679244
年龄 18 岁 至 80 岁(登记的条件)
牵头:复旦大学附属华山医院;另有 2 家列出的医院为研究中心上海
- 正在招募Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
- 分期
- II期
- 开始
- 2023-10
- 登记号
- NCT06054906
年龄 18 岁 至 未注明(登记的条件)
牵头:复旦大学附属华山医院上海
- 即将招募Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer
- 分期
- II期
- 开始
- 2025-05
- 登记号
- NCT06759233
年龄 18 岁 至 80 岁(登记的条件)
牵头:复旦大学附属华山医院上海
- 即将招募A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer
- 分期
- II期
- 开始
- 2025-05
- 登记号
- NCT06957977
年龄 18 岁 至 未注明(登记的条件)
牵头:复旦大学附属华山医院上海
- 正在招募Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- 分期
- 未注明
- 开始
- 2022-09
- 登记号
- NCT06822413
年龄未注明(登记的条件)
牵头:浙江大学医学院附属第二医院;另有 3 家列出的医院为研究中心上海、南昌、杭州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文22
- Neuroactive ligand-receptor interaction in gastric cancer: a comprehensive spatial single-cell analysis.
- Application of Hao's Esophagogastrostomy by Fissure Technique (HEFT) in proximal gastrectomy: protocol for a prospective, multicentre, randomised controlled study.
- Spatiotemporal Correlation Analysis for the Incidence of Esophageal and Gastric Cancer From 2010 to 2019: Ecological Study.
- Shortcoming of ypStage staging system: Lack of differentiation for preoperative treatment.
- A novel anti-reflux esophagogastric anastomosis in totally laparoscopic proximal gastrectomy: Hao's esophagogastrostomy by fissure technique (HEFT).
- Circular RNA hsa_circ_0004650 Enhances 5-Fluorouracil Resistance in Gastric Cancer via Sponging miR-145-5p.
- Elucidating epigenetic landscape of gastric premalignant lesions through genome-wide mapping of 5-hydroxymethylcytosines: A 12-year median follow-up study.
- The safety and feasibility assessment of overlap esophagojejunostomy with self-pulling and latter transection technique in totally laparoscopic total gastrectomy.
- New purse-string suture clamp and multi-functional seal cap: a simple intracorporeal circular-stapled oesophagojejunostomy after laparoscopic total gastrectomy.
- Reconstruction using the colon or jejunum in patients with synchronous advanced esophageal and gastric cancers: a retrospective study from a single institutional database.
- Identification of three lncRNA-related prognostic signatures in gastric cancer by integrated multi-omics analysis.
- The global, regional, and national burden of stomach cancer among adolescents and young adults in 204 countries and territories, 1990-2019: A population-based study.
- Systematic single-cell dissecting reveals heterogeneous oncofetal reprogramming in the tumor microenvironment of gastric cancer.
- Screening and Bioinformatics Analyses of Key miRNAs Associated with Toll-like Receptor Activation in Gastric Cancer Cells.
- Exosome-mediated transfer of circ_0063526 enhances cisplatin resistance in gastric cancer cells via regulating miR-449a/SHMT2 axis.
- Effect of different oesophagojejunostomy methods on the quality of life of gastric cancer patients after totally laparoscopic total gastrectomy with self-pulling and latter transected technique: study protocol for a randomised trial.
- Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study.
- Bracket-like suture method: a novel, circular marked, simplest sided purse-string suture technique for intracorporeal circular-stapled oesophagojejunostomy during laparoscopic total gastrectomy.
- The regulation of hsacirc_004413 promotes proliferation and drug resistance of gastric cancer cells by acting as a competing endogenous RNA for miR-145-5p.
- LINC00511 promotes gastric cancer progression by regulating SOX4 and epigenetically repressing PTEN to activate PI3K/AKT pathway.
- Handover method: Simple, classic and harmonized intracorporeal closure of stapled duodenal stump during laparoscopic gastrectomy.
- The safety and feasibility of intra-corporeal gastroduodenostomy using a self-pulling and latter transected method (Delta SPLT) in totally laparoscopic distal gastrectomy.
中文论文(未计入)2
- [A novel exploration of circular-stapled esophagojejunostomy in totally laparoscopic total gastrectomy: purse-string suture device with multi-functional seal cap].
- [Laparoscopic circular stapled gastrointestinal anastomosis using novel device of sealed cap access after total laparoscopic gastrectomy].
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
- A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
- Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
- A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
- Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
- Metronomic Chemotherapy in Advanced Gastric Cancer
- Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer
- A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer
- Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer
- The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant Ascites
- Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
- Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 3.8%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 15 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
这些数字背后的记录
牵头的论文4
- Proteogenomic characterization of skull-base chordoma.
- Machine learning prediction of venous thromboembolism after surgeries of major sellar region tumors.
- Primary Skull Base Chordomas: A Clinicopathological Analysis of 94 Patients.
- How I do it? Resection of residual petrous apex chordoma with combined endoscopic endonasal and contralateral transmaxillary approaches.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)4
- Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study.
- Mechanisms underlying the promotion of osteosarcoma cell proliferation and invasion by lncRNA PBB12.
- Biocompatibility evaluation of antibacterial Ti-Ag alloys with nanotubular coatings.
- Gabapentin as an Adjuvant Therapy for Prevention of Acute Phantom-Limb Pain in Pediatric Patients Undergoing Amputation for Malignant Bone Tumors: A Prospective Double-Blind Randomized Controlled Trial.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 34 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 15 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 16 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。
这些数字背后的记录
牵头的论文5
- Enhanced clinical outcomes with radiotherapy in diagnostically challenging intracranial plasmacytomas: Analysis of 190 cases.
- Discovery of CZL-046 with an (S)-3-Fluoropyrrolidin-2-one Scaffold as a p300 Bromodomain Inhibitor for the Treatment of Multiple Myeloma.
- Risk nomogram for assessing renal recovery in patients with newly diagnosed multiple myeloma-related renal impairment.
- A novel Twist1/hsa-miR138-5p/caspase-3 pathway regulates cell proliferation and apoptosis of human multiple myeloma.
- Sirtuin 2 knockdown inhibits cell proliferation and RAS/ERK signaling, and promotes cell apoptosis and cell cycle arrest in multiple myeloma.
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 9 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 23 篇,占 4.7%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 4 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募HANDLE-a Real World Study on Satralizumab in NMOSD
- 分期
- 未注明
- 开始
- 2025-03
- 登记号
- NCT06829524
年龄 12 岁 至 未注明(登记的条件)
牵头:复旦大学附属华山医院上海
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文23
- Concomitant Sjögren's disease in patients with NMOSD: impacts on neurologic disease severity and recurrence.
- Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab.
- Outcomes and predictors of relapse and severe pneumonia in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder receiving inebilizumab: a prospective cohort study.
- Dysregulated Tfh/B cells and their interactions in neuromyelitis optica spectrum disorder.
- Eculizumab for the acute attack of neuromyelitis optica spectrum disorder.
- Comparison of the clinical and laboratory characteristics of neuromyelitis optica spectrum disorder with or without cerebrospinal fluid oligoclonal bands: a cohort with 36-month follow-up.
- Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis optica spectrum disorder.
- KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort.
- First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders.
- Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.
- Causal associations between prodromal infection and neuromyelitis optica spectrum disorder: A Mendelian randomization study.
- Clinical feature and disease outcome in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder: a Chinese study.
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.
- Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.
- Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.
- Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.
- Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis.
- The description of neuromyelitis optica spectrum disorder: Patient registry in Yangtze River Delta area of China.
- Longitudinal evaluation of clinical characteristics of Chinese neuromyelitis optica spectrum disorder patients with different AQP4-IgG serostatus.
- Efficacy and safety of rehabilitation exercise in neuromyelitis optica spectrum disorder during the acute phase: A prospective cohort study.
- Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients.
- Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
- Low-dose tacrolimus in treating neuromyelitis optica spectrum disorder.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
PubMed 以外找到的论文(未计入)5
- B-103 KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort
- Satralizumab Treatment in Chinese Patients with AQP4-ab-positive Neuromyelitis Optica Specturm Disorder: A Prospective Study (P9-1.015)
- The effect of health-related hardiness education in patients with neuromyelitis optica spectrum disorders
- Neuromyelitis optica spectrum disorders and pregnancy
- Is low threshold of B cells an obligatory monitoring indicator of repeated RTX infusion in the treatment of Neuromyelitis Optica spectrum disorder? – A report of two cases
其他疾病
IgG4相关性疾病
IgG4-related disease2021–2025 年没有牵头IgG4相关性疾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 4 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。
这些数字背后的记录
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 31 篇,占 6.2%。
上海有 7 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
这家医院参与的开放试验 11
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
- 分期
- 未注明
- 开始
- 2024-02
- 登记号
- NCT04535843
年龄 0 岁 至 90 岁(登记的条件)
牵头:复旦大学附属华山医院;另有 1 家列出的医院为研究中心上海
- 正在招募Myasthenia Gravis Registry in China
- 分期
- 未注明
- 开始
- 2024-02
- 登记号
- NCT06241521
年龄未注明(登记的条件)
牵头:复旦大学附属华山医院;另有 15 家列出的医院为研究中心上海、北京、南昌、天津、广州、徐州、成都、苏州、西安、郑州、重庆、长春、长沙
- 正在招募Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
- 分期
- 未注明
- 开始
- 2023-08
- 登记号
- NCT07146425
年龄 18 岁 至 未注明(登记的条件)
牵头:复旦大学附属华山医院上海
- 即将招募An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- 分期
- I期
- 开始
- 2025-02
- 登记号
- NCT06759948
年龄 18 岁 至 75 岁(登记的条件)
牵头:复旦大学附属华山医院上海
- 正在招募A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
- 分期
- II期
- 开始
- 2026-08
- 登记号
- NCT07622342
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、长沙
- 正在招募Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
- 分期
- I期
- 开始
- 2025-09
- 登记号
- NCT07215650
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、天津、太原、广州、成都、贵阳、郑州、长春
- 正在招募A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- 分期
- II/III期
- 开始
- 2024-07
- 登记号
- NCT06447597
年龄 18 岁 至 70 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、广州、成都、杭州、武汉、济南、西安、长春、长沙
- 正在招募Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- 分期
- III期
- 开始
- 2024-06
- 登记号
- NCT06463587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、广州、成都、武汉、沈阳、石家庄、蚌埠、遵义、郑州、长春、长沙
- 正在招募Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- 分期
- II期
- 开始
- 2022-07
- 登记号
- NCT05067348
年龄 18 岁 至 80 岁(登记的条件)
牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心上海、北京、天津、成都、西安、长沙
- 正在招募A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- 分期
- III期
- 开始
- 2021-07
- 登记号
- NCT04951622
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙
- 即将招募An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
- 分期
- I期
- 开始
- 2026-09
- 登记号
- NCT07818291
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、北京
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文31
- In-Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis.
- Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis.
- Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab.
- Association of blocking acetylcholine receptor antibodies with clinical subtypes and disease severity in myasthenia gravis.
- Efgartigimod versus standard of care in new-Onset AChR subtype generalized myasthenia gravis: A prospective cohort study.
- Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment.
- Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis.
- Distal muscle weakness as the main onset symptom in thymoma-associated myasthenia gravis: a case report and literature review.
- Clinical outcome and peripheral CD4+ T profile in impending myasthenic crisis: A prospective cohort study.
- Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series.
- The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.
- Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China.
- A predictive nomogram for short-term outcomes of myasthenia gravis patients treated with low-dose rituximab.
- Clinical outcome and peripheral immune profile of myasthenic crisis with omicron infections: A prospective cohort study.
- Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series.
- Nomogram for predicting pregnancy-related relapse of myasthenia gravis.
- Autoantibody levels as biomarkers of disease activity in the management of myasthenia gravis.
- Peripheral immune landscape for hypercytokinemia in myasthenic crisis utilizing single-cell transcriptomics.
- Myasthenic crisis in thymoma-associated myasthenia gravis: a multicenter retrospective cohort study.
- Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis.
- Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: A prospective cohort study.
- Pneumonia in myasthenia gravis: Microbial etiology and clinical management.
- Herpesvirus entry mediator on T cells as a protective factor for myasthenia gravis: A Mendelian randomization study.
- A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation.
- Berberine attenuates experimental autoimmune myasthenia gravis via rebalancing the T cell subsets.
- Pneumonia and systemic inflammatory response syndrome as predictors for difficult-/prolonged-weaning after invasive ventilation in myasthenic crisis: A retrospective analysis of a Chinese cohort.
- Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis.
- In-depth peripheral CD4+ T profile correlates with myasthenic crisis.
- The role of innate immunity in myasthenia gravis.
- Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis.
- Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
它在 ClinicalTrials.gov 上的全部试验(任何状态)24
- Myasthenia Gravis Registry in China
- Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
- Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
- Study of Myasthenic Crisis in China
- Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study
- An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
- An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
- A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
- Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
- A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
- Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
- Study of Telitacicept in Generalized Myasthenia Gravis
- Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis
- A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
- Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
- A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG Patients
- A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia Gravis
其他疾病
烟雾病
Moyamoya disease2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 17 篇,占 4.8%。
- 牵头的开放试验
- 0
- 正在或即将招募
上海有 4 家医院列在烟雾病下全国有 47 家医院列在烟雾病下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- 分期
- 未注明
- 开始
- 2026-08
- 登记号
- NCT07894107
年龄 12 岁 至 70 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州
- 正在招募Registry of Multicenter Brain-Heart Comorbidity in China
- 分期
- 未注明
- 开始
- 2012-01
- 登记号
- NCT05961748
年龄 18 岁 至 未注明(登记的条件)
牵头:首都医科大学附属北京天坛医院;另有 4 家列出的医院为研究中心上海、北京、哈尔滨、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文17
- Non-Invasive Diagnosis of Moyamoya Disease Using Serum Metabolic Fingerprints and Machine Learning.
- Inhalational versus intravenous anesthetic for cerebrovascular accident outcomes after surgical revascularization for adult moyamoya disease.
- The cerebellar glucose metabolism in moyamoya vasculopathy and its correlation with neurocognitive performance after cerebral revascularization surgery: a [18F]FDG PET study.
- In-depth cerebrovascular lipidomics profiling for discovering novel biomarkers and mechanisms in moyamoya and intracranial atherosclerotic disease.
- Individualised evaluation based on pathophysiology for moyamoya vasculopathy: application in surgical revascularisation.
- How I do it: direct pressure measurement in moyamoya bypass.
- Brain perfusion, cognition, and plasma Alzheimer's biomarkers in moyamoya disease.
- 18F-FDG PET and a classifier algorithm reveal a characteristic glucose metabolic pattern in adult patients with moyamoya disease and vascular cognitive impairment.
- Learning spatiotemporal features of DSA using 3D CNN and BiConvGRU for ischemic moyamoya disease detection.
- How I do it: superficial temporal artery to middle cerebral artery bypass for moyamoya disease.
- A Review of Artificial Intelligence in Cerebrovascular Disease Imaging: Applications and Challenges.
- Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.
- Application of intraoperative electrocorticography in bypass surgery for adult moyamoya disease: a preliminary study.
- The First 24 h Hemodynamic Management in NICU after Revascularization Surgery in Moyamoya Disease.
- Introduction. Translational research advances in the evaluation and management of moyamoya disease.
- Faded Critical Dynamics in Adult Moyamoya Disease Revealed by EEG and fMRI.
- Preliminary Study on the Application of Ultrahigh Field Magnetic Resonance in Moyamoya Disease.
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Neurocognitive and Radiological Assessments in Adult Moyamoya Undergoing Surgery
- The Adult Hemorrhagic Moyamoya Surgery Study
- Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- Registry of Multicenter Brain-Heart Comorbidity in China
PubMed 以外找到的论文(未计入)12
- Dual-Branch X-CLIP with Feature Purification for Multi-Section DSA Imaging-Based Cerebrovascular Disease Classification
- Perioperative management for patients with moyamoya disease: complications’ definition, technical advances, and outcomes
- 3D DSA-Guided Keyhole STA-MCA Bypass in Moyamoya Vasculopathy
- Intraoperative contrast-enhanced ultrasound evaluates the hemodynamic change of cerebral revascularization in adult moyamoya disease: Preliminary results
- The Role of Flow-Augmentation Bypass in Moyamoya Disease and Hemodynamic Ischemic Stroke
- Analysis of middle cerebral artery blood flow in moyamoya disease and comparison of orthodromic and antidromic bypass
- Identification of Vascular Cognitive Impairment in Adult Moyamoya Disease via Integrated Graph Convolutional Network
- Computational Fluid Dynamics Study of Cerebral Revascularization for Moyamoya Disease
- Functional Magnetic Resonance Imaging Study of Cerebral Revascularization in Moyamoya Disease
- Long-Term Outcome in China
- Superficial Temporal Artery-Middle Cerebral Artery Bypass
- Superficial Temporal Artery-Middle Cerebral Artery Bypass Combined with Encephalo-Duro-Myo-Synangiosis in Treating Moyamoya Disease
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 9 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
这些数字背后的记录
早期论文(2016–2020 年)5
- Solitary juxtacortical lesion associated with anti-N-methyl-D-aspartate receptor encephalitis: a case report.
- Anti-N-methyl-D-aspartate receptor encephalitis with accompanying ovarian teratoma in female patients from East China: Clinical features, treatment, and prognostic outcomes.
- Reduced dosage rituximab in the treatment of anti-N-methyl-d-aspartate receptor encephalitis: An observation study in Chinese patients.
- Raised cerebrospinal fluid BAFF and APRIL levels in anti-N-methyl-d-aspartate receptor encephalitis: Correlation with clinical outcome.
- Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies.
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 34 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文7
- Iron dysregulation and ferroptosis are associated with pulmonary fibrosis: Insight from idiopathic pulmonary fibrosis, systemic sclerosis, and COVID-19 patients.
- Icariside II modulates pulmonary fibrosis via PI3K/Akt/β-catenin pathway inhibition of M2 macrophage program.
- Pulmonary fibrosis model of mice induced by different administration methods of bleomycin.
- Network pharmacology and experiments in vivo and in vitro reveal that the Jia-Wei-Bu-Shen-Yi-Qi formula (JWBSYQF) and its active ingredient baicalein ameliorate BLM-induced lung fibrosis in mice via PI3K/Akt signaling pathway.
- Adipose-derived mesenchymal stem cell therapy for reverse bleomycin-induced experimental pulmonary fibrosis.
- Exploring the comorbidity mechanisms between asthma and idiopathic pulmonary fibrosis and the pharmacological mechanisms of Bu-Shen-Yi-Qi decoction therapy via network pharmacology.
- Endocannabinoid signalling/cannabinoid receptor 2 is involved in icariin-mediated protective effects against bleomycin-induced pulmonary fibrosis.
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 10 篇,占 1.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
上海有 17 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Research on Wireless Brain Implant System for General Control of External Devices
- 分期
- 不分期
- 开始
- 2025-03
- 登记号
- NCT06829212
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文10
- Prognostic Value of Cerebrospinal Fluid and Serum Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Correlation Study.
- Integrated profiling of iPSC-derived motor neurons carrying C9orf72, FUS, TARDBP, or SOD1 mutations.
- Inflammation and Brain Structure in Alzheimer's Disease and Other Neurodegenerative Disorders: a Mendelian Randomization Study.
- Brain region-specific synaptic function of FUS underlies the FTLD-linked behavioural disinhibition.
- A new ERBB4 variant in amyotrophic lateral sclerosis type 19: Case report and review of the literature.
- Iron quantitative analysis of motor combined with bulbar region in M1 cortex may improve diagnosis performance in ALS.
- Associations of cardiovascular risk factors and lifestyle behaviors with neurodegenerative disease: a Mendelian randomization study.
- Investigating Casual Associations Among Gut Microbiota, Metabolites, and Neurodegenerative Diseases: A Mendelian Randomization Study.
- The function of FUS in neurodevelopment revealed by the brain and spinal cord organoids.
- UNC13A Gene Brings New Hope for ALS Disease-Modifying Drugs.
早期论文(2016–2020 年)10
- An exon 5 mutation (c.425G>C, p.Gly141Ala) in the SOD1 gene in a Chinese family associated with incomplete penetrance.
- Familial flail leg ALS caused by PFN1 mutation.
- Tau Accumulation via Reduced Autophagy Mediates GGGGCC Repeat Expansion-Induced Neurodegeneration in Drosophila Model of ALS.
- Amyotrophic lateral sclerosis due to a SOD1 mutation and X-linked recessive bulbospinal neuronopathy in a single family.
- Split-hand phenomenon quantified by the motor unit number index for distinguishing cervical spondylotic amyotrophy from amyotrophic lateral sclerosis.
- Radial diffusivity as an imaging biomarker for early diagnosis of non-demented amyotrophic lateral sclerosis.
- The investigation of genetic and clinical features in Chinese patients with juvenile amyotrophic lateral sclerosis.
- Repetitive nerve stimulation as a diagnostic aid for distinguishing cervical spondylotic amyotrophy from amyotrophic lateral sclerosis.
- Compound Muscle Action Potential Decrement to Repetitive Nerve Stimulation Between Hirayama Disease and Amyotrophic Lateral Sclerosis.
- A novel mutation of VAPB in one Chinese familial amyotrophic lateral sclerosis pedigree and its clinical characteristics.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
脊髓性肌萎缩症
Spinal muscular atrophy2021–2025 年中国大陆作者发表的 55 篇脊髓性肌萎缩症 PubMed 英文论文中,这家医院牵头了 11 篇,占 20.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 6 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。
这些数字背后的记录
牵头的论文11
- The clinical characteristics of Hirayama disease in females.
- The role of leisure-time physical activity in maintaining cervical lordosis after anterior cervical fusion and its impact on the motor function in patients with hirayama disease: a retrospective cohort analysis.
- Association of joint hypermobility with range of cervical motion and its impact on the motor unit loss in patients with Hirayama disease.
- Loss of cervical sagittal alignment worsens the cervical spinal lesions in patients with Hirayama disease.
- Changes in Self-Esteem in Patients with Hirayama Disease and its Association with Prognosis After Anterior Cervical Fusion Procedures.
- Efficacy of Anterior Cervical Discectomy and Fusion for Female Patients with Hirayama Disease.
- How to reconstruct the lordosis of cervical spine in patients with Hirayama disease? A finite element analysis of biomechanical changes focusing on adjacent segments after anterior cervical discectomy and fusion.
- Why the patients with Hirayama disease have abnormal cervical sagittal alignment? A radiological measurement analysis of posterior cervical extensors.
- Teaching NeuroImages: Hirayama Disease With Symmetric Atrophy of Bilateral Distal Upper Extremities.
- Quantitative assessment of motor impairment and surgical outcome in Hirayama disease with proximal involvement using motor unit number index.
- The Short-Term to Midterm Follow-Up of Patients with Hirayama Disease After Anterior Cervical Discectomy and Fusion.
早期论文(2016–2020 年)14
- Establishment of a clinician-led guideline on the diagnosis and treatment of Hirayama disease using a modified Delphi technique.
- Analysis of the Effect of Surgical Treatment for the Patients with Hirayama Disease from the Perspective of Cervical Spine Sagittal Alignment.
- Snake-Eyes Appearance on MRI Occurs during the Late Stage of Hirayama Disease and Indicates Poor Prognosis.
- The evaluation on neural status of cervical spinal cord in normal and Hirayama disease using diffusion tensor imaging.
- Factors Affecting the Surgical Outcomes of Hirayama Disease: A Retrospective Analysis of Preoperative Magnetic Resonance Imaging Features of the Cervical Spine.
- CAN anterior cervical fusion procedures prevent the progression of the natural course of Hirayama disease? An ambispective cohort analysis.
- Cortical Activation Changes in Hirayama Disease After Anterior Cervical Decompression and Fusion.
- Dynamic Cervical Radiographs in Patients with Hirayama Disease: An Unneglectable Factor on the Choice of Surgery Options.
- Changes in the soleus H-reflex test and correlations between its results and dynamic magnetic resonance imaging abnormalities in patients with Hirayama disease.
- A double determination of central motor conduction time in the assessment of Hirayama disease.
- Motor unit number estimation in the quantitative assessment of severity and progression of motor unit loss in Hirayama disease.
- Compound Muscle Action Potential Decrement to Repetitive Nerve Stimulation Between Hirayama Disease and Amyotrophic Lateral Sclerosis.
- Risk Factors for Surgical Results of Hirayama Disease: A Retrospective Analysis of a Large Cohort.
- A study of dynamic F-waves in juvenile spinal muscular atrophy of the distal upper extremity (Hirayama disease).
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
庞贝病
Pompe disease2021–2025 年中国大陆作者发表的 30 篇庞贝病 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.3%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 4 家医院列在庞贝病下全国有 30 家医院列在庞贝病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 12 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 15 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 26 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文6
- Renal outcomes in IgA nephropathy following inactivated SARS-CoV-2 vaccination.
- Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Self-Controlled Study.
- Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China.
- Exploring genes for immunoglobulin A nephropathy: a summary data-based mendelian randomization and FUMA analysis.
- Mesangial cell-derived tenascin-C contributes to mesangial cell proliferation and matrix protein production in IgA nephropathy.
- KM55 Monoclonal Antibody Staining in IgA-Dominant Infection-Related Glomerulonephritis.
早期论文(2016–2020 年)2
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 17 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 13 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
其他疾病
遗传性大疱性表皮松解症
Inherited epidermolysis bullosa2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 7 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。
其他疾病
遗传性血管性水肿
Hereditary angioedema2021–2025 年中国大陆作者发表的 32 篇遗传性血管性水肿 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 2 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。
联系这家医院
出示给工作人员或司机的院名卡
复旦大学附属华山医院
Huashan Hospital
上海
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Huashan Hospital Fudan University; Huashan Hospital & Cancer Metastasis Institute; Huashan Hospital North; Huashan Hospital of Fudan University; Huashan Hospital Affiliated to Fudan University; Fudan University Huashan Hospital; Huashan Hospital Shanghai Medical College; Huashan Hospital and Cancer Metastasis Institute